Swiss National Bank Sells 2,600 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Swiss National Bank cut its holdings in shares of Disc Medicine, Inc. (NASDAQ:IRON) by 7.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 32,200 shares of the company’s stock after selling 2,600 shares during the period. Swiss National Bank owned about 0.11% of Disc Medicine worth $2,041,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the business. Wellington Management Group LLP increased its position in Disc Medicine by 4.8% during the 3rd quarter. Wellington Management Group LLP now owns 1,840,226 shares of the company’s stock worth $90,429,000 after purchasing an additional 83,731 shares in the last quarter. State Street Corp grew its stake in shares of Disc Medicine by 39.7% during the third quarter. State Street Corp now owns 827,910 shares of the company’s stock worth $40,683,000 after buying an additional 235,115 shares during the last quarter. Janus Henderson Group PLC increased its holdings in shares of Disc Medicine by 68.2% during the third quarter. Janus Henderson Group PLC now owns 749,827 shares of the company’s stock worth $36,828,000 after buying an additional 303,954 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of Disc Medicine by 17.6% in the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company’s stock valued at $23,333,000 after acquiring an additional 70,983 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its holdings in shares of Disc Medicine by 7.4% during the 4th quarter. Victory Capital Management Inc. now owns 236,244 shares of the company’s stock valued at $14,978,000 after acquiring an additional 16,230 shares in the last quarter. Institutional investors and hedge funds own 83.70% of the company’s stock.

Analyst Upgrades and Downgrades

IRON has been the subject of a number of recent research reports. Stifel Nicolaus upped their target price on Disc Medicine from $90.00 to $94.00 and gave the stock a “buy” rating in a report on Friday, January 24th. Morgan Stanley reiterated an “overweight” rating and issued a $85.00 price objective on shares of Disc Medicine in a report on Friday, March 7th. HC Wainwright reissued a “buy” rating and set a $118.00 target price on shares of Disc Medicine in a report on Tuesday, January 21st. Scotiabank raised their price target on shares of Disc Medicine from $73.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, March 3rd. Finally, TD Cowen started coverage on shares of Disc Medicine in a research note on Thursday, February 27th. They issued a “buy” rating on the stock. Ten equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Disc Medicine has a consensus rating of “Buy” and an average target price of $93.80.

Insider Buying and Selling

In other news, CEO John D. Quisel sold 13,012 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was sold at an average price of $61.95, for a total transaction of $806,093.40. Following the transaction, the chief executive officer now directly owns 72,065 shares of the company’s stock, valued at $4,464,426.75. This represents a 15.29 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Mona Ashiya sold 10,011 shares of Disc Medicine stock in a transaction on Friday, March 21st. The shares were sold at an average price of $54.00, for a total transaction of $540,594.00. Following the completion of the sale, the director now directly owns 187,297 shares of the company’s stock, valued at approximately $10,114,038. The trade was a 5.07 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 382,202 shares of company stock valued at $20,924,812 over the last ninety days. 4.24% of the stock is owned by corporate insiders.

Disc Medicine Trading Down 0.2 %

Shares of Disc Medicine stock opened at $52.36 on Friday. The business has a 50-day moving average price of $54.64 and a two-hundred day moving average price of $56.10. Disc Medicine, Inc. has a 1-year low of $25.60 and a 1-year high of $68.73. The company has a market cap of $1.81 billion, a P/E ratio of -13.16 and a beta of 0.73.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, February 27th. The company reported ($0.98) EPS for the quarter, topping the consensus estimate of ($1.06) by $0.08. Equities research analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current fiscal year.

Disc Medicine Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.